Evidence map›Paper›PMID 23873933›Full record

ArticleThe Journal of biological chemistry2013

Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.

Walid S Maaty, Connie I Lord, Jeannie M Gripentrog, Marcia Riesselman, Gal Keren-Aviram, Ting Liu, Edward A Dratz, Brian Bothner, Algirdas J Jesaitis

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Phosphosite mapping of HIP-55 protein in mammalian cells.International journal of molecular sciences · 2014
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Walid S MaatyDepartments of Chemistry and Biochemistry, Montana State University, Bozeman, Montana 59717.
Connie I LordDepartments of Microbiology.
Jeannie M GripentrogDepartments of Microbiology.
Marcia RiesselmanDepartments of Microbiology.
Gal Keren-AviramDepartments of Chemistry and Biochemistry, Montana State University, Bozeman, Montana 59717.
Ting LiuDepartments of Chemistry and Biochemistry, Montana State University, Bozeman, Montana 59717.
Edward A DratzDepartments of Chemistry and Biochemistry, Montana State University, Bozeman, Montana 59717.
Brian BothnerDepartments of Chemistry and Biochemistry, Montana State University, Bozeman, Montana 59717.
Algirdas J JesaitisDepartments of Microbiology. Electronic address: umbaj@montana.edu.
Montana State University · US

Funding

VIRUSES: FROM PARTICLES TO PROTEOMICSP20RR020185 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI VOYICH, JOVANKA M · 2004 to 2011
$17.0M
SYSTEMS BIOLOGY OF HOST-PATHOGEN INTERACTIONSP20RR024237 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI GAUSS, KATHERINE A. · 2008 to 2011
$8.1M
Center for the Analysis of Cellular Mechanisms and Systems BiologyP20GM103394 · NIGMS · MONTANA STATE UNIVERSITY - BOZEMAN · PI DRATZ, EDWARD A · 2012 to 2013
$3.2M
CCR5 &CXCR4 Antagonist &Agonist Binding Site StructureR01AI064107 · NIAID · MONTANA STATE UNIVERSITY - BOZEMAN · PI DRATZ, EDWARD A · 2005 to 2009
$1.7M
Mapping Adeno-associated Virus Capsid Structural and Dynamic TransitionsR01AI081961 · NIAID · MONTANA STATE UNIVERSITY - BOZEMAN · PI BOTHNER, BRIAN P · 2009 to 2012
$1.4M
Multiplex Fluorescent Dyes for Ultrasensitive ProteomicsR42RR021790 · NCRR · ZDYE, LLC · PI DRATZ, EDWARD A · 2008 to 2010
$1.1M
RREGULATION OF SUPEROXIDE PRODUCTION BY HUMAN NEUTROPHILR01AI022735 · NIAID · SCRIPPS CLINIC AND RESEARCH FOUNDATION · PI JESAITIS, ALGIRDAS JOSEPH · 1985 to 2003
$890k
Enhanced Dynamic Range Proteomic Analysis: Phase IIR42RR025311 · NCRR · RESONON INC. · PI SWANSON, RAND · 2011 to 2011
$398k
NCRR NIH HHS 1R42RR-025311NCRR NIH HHS 2R42RR-021740NCRR NIH HHS 2R42RR-021790NCRR NIH HHS P20 RR020185NCRR NIH HHS P20RR-020185NCRR NIH HHS P20 RR024237NCRR NIH HHS P20RR-024237NCRR NIH HHS R42 RR021790NCRR NIH HHS R42 RR025311NIAID NIH HHS 5R01AI-064107NIAID NIH HHS R01 AI022735NIAID NIH HHS R01 AI064107NIAID NIH HHS R01 AI081961NIAID NIH HHS R01 AI081961-01A1NIAID NIH HHS R01-AI22735-19NIGMS NIH HHS P20 GM103394NIGMS NIH HHS P20GM-103394-05
6 · The paper itself

Abstract

Accumulation, activation, and control of neutrophils at inflammation sites is partly driven by N-formyl peptide chemoattractant receptors (FPRs). Occupancy of these G-protein-coupled receptors by formyl peptides has been shown to induce regulatory phosphorylation of cytoplasmic serine/threonine amino acid residues in heterologously expressed recombinant receptors, but the biochemistry of these modifications in primary human neutrophils remains relatively unstudied. FPR1 and FPR2 were partially immunopurified using antibodies that recognize both receptors (NFPRa) or unphosphorylated FPR1 (NFPRb) in dodecylmaltoside extracts of unstimulated and N-formyl-Met-Leu-Phe (fMLF) + cytochalasin B-stimulated neutrophils or their membrane fractions. After deglycosylation and separation by SDS-PAGE, excised Coomassie Blue-staining bands (∼34,000 Mr) were tryptically digested, and FPR1, phospho-FPR1, and FPR2 content was confirmed by peptide mass spectrometry. C-terminal FPR1 peptides (Leu(312)-Arg(322) and Arg(323)-Lys(350)) and extracellular FPR1 peptide (Ile(191)-Arg(201)) as well as three similarly placed FPR2 peptides were identified in unstimulated and fMLF + cytochalasin B-stimulated samples. LC/MS/MS identified seven isoforms of Ala(323)-Lys(350) only in the fMLF + cytochalasin B-stimulated sample. These were individually phosphorylated at Thr(325), Ser(328), Thr(329), Thr(331), Ser(332), Thr(334), and Thr(339). No phospho-FPR2 peptides were detected. Cytochalasin B treatment of neutrophils decreased the sensitivity of fMLF-dependent NFPRb recognition 2-fold, from EC50 = 33 ± 8 to 74 ± 21 nM. Our results suggest that 1) partial immunopurification, deglycosylation, and SDS-PAGE separation of FPRs is sufficient to identify C-terminal FPR1 Ser/Thr phosphorylations by LC/MS/MS; 2) kinases/phosphatases activated in fMLF/cytochalasin B-stimulated neutrophils produce multiple C-terminal tail FPR1 Ser/Thr phosphorylations but have little effect on corresponding FPR2 sites; and 3) the extent of FPR1 phosphorylation can be monitored with C-terminal tail FPR1-phosphospecific antibodies.

Indexed as

Cytochalasin BHumansNeutrophil ActivationNeutrophilsN-Formylmethionine Leucyl-PhenylalaninePhosphorylationProtein Structure, TertiaryReceptors, Formyl PeptideReceptors, LipoxinCytochalasin BFPR1 protein, humanFPR2 protein, humanN-Formylmethionine Leucyl-PhenylalanineReceptors, Formyl PeptideReceptors, Lipoxin7-Helix ReceptorChemokinesCytochalasin BEpitope Mappingf-Met-Leu-PheFPR PhosphorylationInflammationLC/MS/MSMass Spectrometry (MS)Neutrophil

Identifiers

PMID23873933
PMCPMC3779705
OpenAlexW2014595299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.